| 1 | State of Arkansas | As Engrossed: \$3/13/13 | |
|----|--|--|-------------------------|
| 2 | 89th General Assembly | A Bill | |
| 3 | Regular Session, 2013 | | SENATE BILL 965 |
| 4 | | | |
| 5 | By: Senator J. Dismang | | |
| 6 | | | |
| 7 | For An Act To Be Entitled | | |
| 8 | AN ACT TO AMEND UNCODIFIED SECTION 1 OF ACT 274 OF | | |
| 9 | 2013 TO EXCLUDE CERTAIN DRUGS FROM THE DEFINITION OF | | |
| 10 | THERAPEUT | TIC CLASS; AND FOR OTHER PURPOSES. | |
| 11 | | | |
| 12 | | | |
| 13 | | Subtitle | |
| 14 | TO . | AMEND UNCODIFIED SECTION 1 OF ACT 27 | 4 |
| 15 | OF 2013 TO EXCLUDE CERTAIN DRUGS FROM THE | | |
| 16 | DEF | INITION OF THERAPEUTIC CLASS. | |
| 17 | | | |
| 18 | | | |
| 19 | BE IT ENACTED BY THE | GENERAL ASSEMBLY OF THE STATE OF ARE | KANSAS: |
| 20 | | | |
| 21 | SECTION 1. Und | codified Section 1 of Act 274 of 2013 | 3 is amended to read |
| 22 | as follows: | | |
| 23 | SECTION 1. Arka | ansas Code § 17-92-101(17), concernin | ng the definition of |
| 24 | prescription for the | pharmacy act, is amended to read as $% \left(1\right) =\left(1\right) \left($ | follows: |
| 25 | <u>(17) (A)</u> | "Prescription" means an order for me | edicine or medicines |
| 26 | usually written as a | formula by a physician, optometrist | , dentist, |
| 27 | veterinarian, or othe | er licensed medicinal practitioner. | It contains the |
| 28 | names and quantities | of the desired substance, with instr | ructions to the |
| 29 | pharmacist for its pr | reparation and to the patient for the | e use of the medicine |
| 30 | at a particular time and may authorize the pharmacist to substitute a | | |
| 31 | therapeutically equivalent drug that is at a lower cost to the patient and | | |
| 32 | communicate that authorization by any generally accepted means of | | |
| 33 | communication of a pr | rescription from a prescriber to a pl | narmacist. |
| 34 | <u>(B)</u> |) A substitution of a therapeutical | Ly equivalent drug |
| 35 | shall occur only afte | er the prescriber grants such author | <u>ization for each</u> |
| 36 | prescription. | | |

As Engrossed: S3/13/13

| Ţ | $\frac{(B)(i)(C)(i)}{(C)(i)}$ Before dispensing, the pharmacist shall | | |
|----|--|--|--|
| 2 | discuss verbally any suggested substitution with the patient and inform the | | |
| 3 | patient that the patient has a right to refuse the substitution. | | |
| 4 | (ii) The discussion under subdivision (17)(B)(i) | | |
| 5 | (17)(C)(i) of this section shall include without limitation: | | |
| 6 | (a) Notification to the patient that the | | |
| 7 | therapeutically equivalent drug does not contain the identical active | | |
| 8 | ingredient present in the prescribe prescribed drug; and | | |
| 9 | (b) All differences in dosage and frequency | | |
| 10 | between the prescribed drug and the therapeutically equivalent drug. | | |
| 11 | (C)(D) The pharmacist shall send notice of the | | |
| 12 | substitution to the prescriber in writing or by electronic communication | | |
| 13 | within twenty-four (24) hours after the drug is dispensed to the patient. | | |
| 14 | (E) Subdivision $(17)(B)$ of this section does not apply to | | |
| 15 | specific acts of drug therapy management or disease state management | | |
| 16 | delegated to a pharmacist based upon a written protocol or patient care plan | | |
| 17 | approved by a physician under § 17-92-101(16)(A)(ix); | | |
| 18 | | | |
| 19 | /s/J. Dismang | | |
| 20 | | | |
| 21 | | | |
| 22 | | | |
| 23 | | | |
| 24 | | | |
| 25 | | | |
| 26 | | | |
| 27 | | | |
| 28 | | | |
| 29 | | | |
| 30 | | | |
| 31 | | | |
| 32 | | | |
| 33 | | | |
| 34 | | | |
| 35 | | | |
| 36 | | | |